Trial Profile
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Sep 2022.
- 22 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Sep 2022.
- 08 May 2017 Status changed from not yet recruiting to recruiting.